Multivessel PCI on top of culprit lesion revascularization? No way!

Slides:

Advertisements

Similar presentations

Clinique Médicale du Ring

Advertisements

When PCI in NSTEMI? Giuseppe Biondi Zoccai, MD Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome.

STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.

Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.

Pros and cons of FFR in multivessel disease: from FAME to ACS Giuseppe Biondi Zoccai University of Modena and Reggio Emilia, Modena, Italy

FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.

To stent or not to stent Clinical Utility of Fractional Flow Reserve.

Journal : Evidence Review PCI : Role of FFR Dr Binjo J Vazhappilly SR Cardiology MCH Calicut.

CORONARY PRESSURE MEASURENT AND FRACTIONAL FLOW RESERVE

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Biondi-Zoccai: Peripheral interventions – metcardio.org Basic principles of peripheral interventions Giuseppe Biondi Zoccai University.

Multi-vessel disease and intracoronay physiology Combat MI 2009 Kees-joost Botman MD, PhD Catharina hospital Eindhoven Heart Institute The Netherlands.

RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.

Elective Stenting versus Balloon Angioplasty with Bail-out Stenting for Small Vessel Coronary Artery Disease: Evidence from a Meta-analysis of Randomized.

Culprit vessel vs Multi vessel PCI in STEMI

PCI vs. CABG: Review of the evidence and suggestions Giuseppe Biondi Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.

SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.

Intravascular ultrasound does not provide any significant clinical benefit for percutaneous coronary intervention of bifurcation lesions Giuseppe Biondi.

COMPLETE REVASCULARIZATION IN ELDERLY - When it’s contraindicated

Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy JOINT SYMPOSIUM WITH JACCT - Bologna, 25/9/2008.

Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.

PRACTICAL RECOMMENDATIONS ON ANTI- THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista.

Could an antianginal metabolic agent have an impact on prognosis in ischemic patients? Beneficial effects of trimetazidine in patients with acute myocardial.

Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.

Thrombectomy: beneficial (if ever) only in highly selected patients Prof. Imad Sheiban University of Turin, Turin, Italy.

ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.

Drug-eluting stent meta-analyses & Long-term follow-up of high-risk subsets: Reconciling the evidence DES e BMS: riflessioni e pensieri 23 febbraio 2007,

1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.

Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy BMS & Sanofi Aventis Sponsored.

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

Multivessel PCI in an Era of Freedom and FAME Michael J. Cowley, MD, FSCAI Nothing to Disclose.

Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Are the Culprit Lesions Severely Stenotic? J Am Coll.

Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.

Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.

Solved & Unsolved Issues

Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.

Impella 2.5® Device Is Associated with Improved Survival in AMICS

The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions

AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.

Giuseppe Biondi Zoccai

Giuseppe Biondi Zoccai

Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,

Primary endpoint at 1 year

The American College of Cardiology Presented by Dr. Maurits T. Dirksen

Background There is ongoing debate to identify the most effective drug-eluting stent between the two currently most used devices (ie, sirolimus- [SES]

Giuseppe Biondi Zoccai University of Turin, Turin, Italy

Nat. Rev. Cardiol. doi: /nrcardio

Giuseppe Biondi Zoccai, MD

Figure 1 PCI strategies in patients with STEMI and multivessel disease

Nat. Rev. Cardiol. doi: /nrcardio

Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.

Preventive Angioplasty in Myocardial Infarction Trial

SURGERY EARLY AFTER DES IMPLANTATION

Benefits of complete coronary revascularization – Counterpoint: what are you talking about? Giuseppe Biondi Zoccai, MD University of Modena and Reggio.

(p = 0.32 for noninferiority)

Figure 4 Observational studies on multiple treatment strategies

O.L.Reuchlin gebruik van CT binnen de cardiogie

CHRONIC TOTAL OCCLUSIONS: WHAT IS KNOWN AND

Role of Stenting in Acute MI: PAMI Stent Pilot Trial

Single Versus Multiple Vessel Stenting In Patients With St-Elevation Myocardial Infarction: Results From A 30,886-Patient Meta-Analysis Giuseppe Biondi.

SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.

Nat. Rev. Cardiol. doi: /nrcardio

Maintenance of Long-Term Clinical Benefit with

Is Prasugrel Superior To Ticagrelor For The Treatment Of Patients With Acute Coronary Syndromes? Evidence From A 32,893-Patient Adjusted Indirect Comparison.

Dye strongly persistent

The American College of Cardiology Presented by Dr. A. Abazid

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

Javier Escaned et al. JCIN 2018;11:

Cardiovascular Epidemiology and Epidemiological Modelling

Presentation transcript:

Multivessel PCI on top of culprit lesion revascularization? No way!

Major issues How do you define complete revascularization in multivessel disease (MVD)? What is the risk-benefit balance of culprit vs multivessel PCI in stable MVD? What is the risk-benefit balance of culprit vs multivessel PCI in acute MVD?

Let us begin with an example from a related field…

Is it safer to target one only?

Or all of them at once?

Major issues How do you define complete revascularization in multivessel disease (MVD)? What is the risk-benefit balance of culprit vs multivessel PCI in stable MVD? What is the risk-benefit balance of culprit vs multivessel PCI in acute MVD?

Defining revascularization Anatomically complete: PCI of every occluded or stenotic epicardial vessel Functionally complete: PCI of every occluded or stenotic epicardial vessel of adequate size and supplying a zone of viable myocardium Incomplete (culprit only): PCI of occluded or stenotic epicardial vessel identified by clinical judgement as responsible for signs/symptoms of ischemia Incomplete (truly): everything else

Hazards of multivessel stenting

Orlic et al, JACC 2004

Major issues How do you define complete revascularization in multivessel disease (MVD)? What is the risk-benefit balance of culprit vs multivessel PCI in stable MVD? What is the risk-benefit balance of culprit vs multivessel PCI in acute MVD?

PCI based only on oculostenotic reflex is not justified in stable MVD

Boden et al, NEJM 2007

Even symptomatic benefits are only marginal in unselected patients Boden et al, NEJM 2007

Would you trust an hazard ratio of 1.15?

Major issues How do you define complete revascularization in multivessel disease (MVD)? What is the risk-benefit balance of culprit vs multivessel PCI in stable MVD? What is the risk-benefit balance of culprit vs multivessel PCI in acute MVD?

PCI based only on oculostenotic reflex is also not justified in acute MVD Hirsch et al, Lancet 2007

Multivessel PCI in acute MVD: incremental benefits or costs? Brener et al, Am J Cardiol 2002

What about complete PCI in STEMI? Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. Di Mario C, Mara S, Flavio A, Imad S, Antonio M, Anna P, Emanuela P, Stefano DS, Angelo R, Stefania C, Anna F, Carmelo C, Antonio C, Monzini N, Bonardi MA. Int J Cardiovasc Intervent. 2004;6(3-4):

53 vs 69 minutes, p< vs 4%, p=NS 35% vs 17% p=NS 22,330€ vs 20,382€, p=NS Di Mario et al, Int J Cardiovasc Intervent 2004

Take home messages Current data disCOURAGE from extensive multivessel PCI based only on angiographic assessment in stable MVD No definite benefits have been shown from multivessel PCI in patients with acute CAD and MVD (either STEMI or NSTEACS) According to evidence available to date, PCI of non-culprit vessels can thus be recommended only is selected cases

For further slides on these topics please feel free to visit the metcardio.org website: